Kairos Pharma, Ltd. (KAPA)

Kairos Pharma Statistics

Total Valuation

Kairos Pharma has a market cap or net worth of $11.09 million. The enterprise value is $7.99 million.

Market Cap	11.09M
Enterprise Value	7.99M

Important Dates

The last earnings date was Wednesday, May 13, 2026, after market close.

Earnings Date	May 13, 2026
Ex-Dividend Date	n/a

Share Statistics

Kairos Pharma has 21.41 million shares outstanding. The number of shares has increased by 55.40% in one year.

Current Share Class	21.41M
Shares Outstanding	21.41M
Shares Change (YoY)	+55.40%
Shares Change (QoQ)	+0.78%
Owned by Insiders (%)	36.51%
Owned by Institutions (%)	6.94%
Float	12.42M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	2.20
P/TBV Ratio	2.21
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 10.31

Current Ratio	10.31
Quick Ratio	8.53
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -93.84% and return on invested capital (ROIC) is -60.22%.

Return on Equity (ROE)	-93.84%
Return on Assets (ROA)	-54.78%
Return on Invested Capital (ROIC)	-60.22%
Return on Capital Employed (ROCE)	-112.86%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	n/a
Profits Per Employee	-$1.46M
Employee Count	4
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -8.79% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-8.79%
50-Day Moving Average	0.57
200-Day Moving Average	0.86
Relative Strength Index (RSI)	45.06
Average Volume (20 Days)	177,784

Short Selling Information

The latest short interest is 125,693, so 0.59% of the outstanding shares have been sold short.

Short Interest	125,693
Short Previous Month	236,224
Short % of Shares Out	0.59%
Short % of Float	1.01%
Short Ratio (days to cover)	1.36

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-6.00M
Pretax Income	-5.84M
Net Income	-5.84M
EBITDA	-5.84M
EBIT	-6.00M
Earnings Per Share (EPS)	-$0.30

Balance Sheet

The company has $3.68 million in cash and n/a in debt, with a net cash position of $3.68 million or $0.17 per share.

Cash & Cash Equivalents	3.68M
Total Debt	n/a
Net Cash	3.68M
Net Cash Per Share	$0.17
Equity (Book Value)	5.31M
Book Value Per Share	0.25
Working Capital	4.01M

Cash Flow

Operating Cash Flow	-3.76M
Capital Expenditures	n/a
Depreciation & Amortization	160,000
Net Borrowing	3.60M
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Kairos Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-55.40%
Shareholder Yield	-55.40%
Earnings Yield	-50.04%
FCF Yield	n/a

Analyst Forecast

The average price target for Kairos Pharma is $8.00, which is 1,444.70% higher than the current price. The consensus rating is "Buy".

Price Target	$8.00
Price Target Difference	1,444.70%
Analyst Consensus	Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2